ArticleNutrients2024
Article in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Anti-Adipogenic Effects of Probiotic Lactiplantibacillus pentosus THF59 via Inhibition of Differentiation and Promotion of Apoptosis in 3T3-L1 Cells.Probiotics and antimicrobial proteins · 2026Article
- Adenosine from high-fat-diet-tolerant monkey-derived Limsolactobacillus reuteri MacFasB02 modulates cholesterol metabolism to alleviate hyperlipidemia and inflammation.NPJ science of food · 2026Article
- Serum Uric Acid-Reducing Effect and Intestinal Mucosal Barrier-Repairing Function ofMicroorganisms · 2026Article
- The impact of antibiotic exposure on obesity and metabolic phenotypes via the gut microbiota.Frontiers in microbiology · 2026Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesThe purpose of this study was to find the potential mechanism of two Lactobacillus (
methodsIn this study, mice with HFD supplemented with L11 or LR exhibited slower obesity progression, including reduced weight gain, abdominal fat accumulation, liver damage, inflammation, and adipose lesions.
resultsTotal cholesterol (TC) and triglycerides (TG) in the serum were significantly reduced (
conclusionsL11 and LR can effectively reduce obesity by modulating gut microbiota and activating the PPAR-AMPK pathway, leading to decreased liver injury and systemic inflammation in mice fed with an HFD. In the future, the two probiotics may provide a new way for clinically ameliorating obesity on human beings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.